Clinical Trial Update: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This document announces a Phase 2 clinical trial evaluating JNJ-79635322 in relapsed or refractory multiple myeloma and notes that it is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• JNJ-79635322

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING